Egfr Mutations Websites
IRESSA® (gefitinib) | Information and resources
Learn about IRESSA (gefitinib), now approved for first-line treatment of EGFR mutation–positive patients with metastatic NSCLC
Not Applicable
$
8.95
Learn about IRESSA (gefitinib), now approved for first-line treatment of EGFR mutation–positive patients with metastatic NSCLC
Not Applicable
$
8.95
